Squadron Master Fund LP, Squadron Capital Management LLC, Matthew Sesterhenn, and William Blank jointly filed an amended beneficial ownership statement with the SEC on November 16, 2026, disclosing that each reporting person holds zero shares of InMed Pharmaceuticals Inc. common stock as of September 30, 2026.

Key Highlights

  • Four reporting persons: Squadron Master Fund LP, Squadron Capital Management LLC, Matthew Sesterhenn, and William Blank are each named in this Amendment No. 1 filing.
  • Zero beneficial ownership: Each reporting person reports 0 shares beneficially owned, representing 0.0% of InMed Pharmaceuticals' common shares.
  • No voting or dispositive power: All four filers report 0 shares with sole or shared voting power, and 0 shares with sole or shared dispositive power.
  • Triggering event date: The date of the event requiring this filing is stated as September 30, 2026.
  • Ownership threshold: The filing invokes Item 5, "Ownership of 5 Percent or Less of a Class," indicating the aggregate position is at or below that threshold.
  • Issuer headquarters: InMed Pharmaceuticals Inc. is headquartered at 510 West Georgia St., Suite 1800, Vancouver, British Columbia, Canada, V6B 0M3, according to the filing.

Squadron Group Reports Complete Exit from InMed Pharmaceuticals Position

According to the filing, Squadron Master Fund LP is organized in Delaware and operates through Squadron Partners LLC as its general partner, with Matthew Sesterhenn signing in his capacity as Partner. Squadron Capital Management LLC, also a Delaware entity, is identified as an investment adviser and holding company. Matthew Sesterhenn and William Blank, both United States citizens, are listed individually as holding company persons and individuals, all sharing the same registered address at 1211 West 22nd Street, Suite 1008, Oak Brook, IL 60523.

InMed Pharmaceuticals Inc. is a pharmaceutical company whose common shares carry no par value and are identified under CUSIP number 457637700. The filing is designated Amendment No. 1, indicating a prior statement was on record for this group of filers. As of the September 30, 2026 event date, the filing discloses that each of the four reporting persons holds an aggregate beneficial ownership of 0 shares, with 0% of the class represented, covering all categories of sole and shared voting and dispositive power.

The certifications included in the filing state that, to the best of the signatories' knowledge and belief, the securities were acquired and are held in the ordinary course of business and "were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." Item 6 (ownership on behalf of another person) and Items 7, 8, and 9 are each noted as "Not Applicable" in the disclosure.

What Was Disclosed

This Amendment No. 1 filing reports that Squadron Master Fund LP, Squadron Capital Management LLC, Matthew Sesterhenn, and William Blank collectively hold zero beneficial shares of InMed Pharmaceuticals Inc. common stock as of September 30, 2026, down to 0.0% of the class.